$COCP News

Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation

Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And Influenza

Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000K

Cocrystal Pharma Features Mechanism Of Action And Clinical Advancement Of Oral Protease Inhibitor CDI-988 In Oral Presentation At 39th ICAR 2026

Cocrystal Pharma Files $150M Shelf Offering To Sell Stock, Warrants, And Other Securities

Why Cocrystal Pharma Shares Are Cooling Off Monday?

Cocrystal Pharma shares are trading higher after the company announced that the FDA has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.

Cocrystal Pharma shares are trading higher after the company announced that the FDA has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.

Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988

Cocrystal Pharma Says FDA Grants Fast Track Designation To Its Direct-Acting Protease Inhibitor, CDI-988, Oral Antiviral Candidate Being Developed For Treatment And Prophylaxis Of Norovirus Infection

Cocrystal Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate

Cocrystal Pharma Announces First Subjects Dosed In Phase 1b Norovirus Challenge Study To Evaluate CDI-988 As Both Preventive And Treatment For Norovirus Infections

COCP: CDI-988 Data to be Presented at ICAR 2026

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Cocrystal Pharma Receives IRB Approval From Emory University School Of Medicine For Phase 1b Human Challenge Study With CDI-988 In Prevention And Treatment of Norovirus

Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference

COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26…

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Expects To Initiate CDI-988 Phase 1b Norovirus Challenge Study In Q1 2026